Widely reported research published Tuesday in the medical journal, The Lancet, spells good news for a Marlborough company that less than two months ago executed a 100-for-1 reverse stock split to dig itself out of penny stock territory. Advanced Cell Technology today announced that results from an early-stage trial indicating that its treatment helped improve vision in 10 out of 18 patients with two kinds of macular degeneration - an eye disease that can lead to blindness.
http://ift.tt/1sSZG5Q
http://ift.tt/1sSZG5Q
No comments:
Post a Comment